Siemens Healthineers has launched Accela, a radiotherapy system that enables single breath-hold stereotactic treatments and multi-site SBRT treatment in as little as 60 seconds. The technology significantly reduces patient time on the treatment table and shortens the overall course of treatment. The company describes Accela as the first radiotherapy system with these capabilities. The announcement was made on 27 September 2026.

The Advanced Research Projects Agency for Health has awarded Siemens Healthineers up to $31.1 million over five years to develop autonomous remote endovascular robotics for acute stroke treatment. Siemens will contribute an additional $5.4 million, bringing total investment to $36.5 million. The technology aims to enable robots to perform mechanical thrombectomy — a procedure that removes blood clots from brain blood vessels — without direct human input. Currently, only an estimated 12% of 335,000 eligible US stroke patients receive this treatment annually, as more than half the population lives over an hour from a thrombectomy-capable clinic. The funding is part of ARPA-H's Autonomous Interventions and Robotics programme. Stryker is participating as a sub-awardee, building on a 2025 partnership with Siemens.

Siemens Healthineers has launched capillary blood testing on its Atellica CH, IM, and CI Analysers after receiving CE-mark approval for 24 assays. The capability enables clinical laboratories to perform common tests including metabolic panels, lipid panels, thyroid, Vitamin D, and HbA1c using finger prick or heel stick samples rather than standard blood draws. Capillary testing offers a patient-friendly alternative for individuals with difficult veins, low blood volume, needle phobia, or disabilities. The validated claims provide laboratories with confidence in test results whilst expanding testing capabilities using existing infrastructure. In the United States, Siemens Healthineers currently offers four assays with capillary claims and is pursuing additional approvals with the FDA. The company aims to make testing more accessible and efficient across core laboratory settings.